Natural Killer Cells 20+ Marketed and Pipeline Drugs Analysis 2017: Competitive Landscape, Pipeline and Industry Outlook

“Natural Killer Cells Therapeutics Pipeline and Market Analysis 2017”
Orbis Research has added “Natural Killer Cells- Competitive Landscape, Pipeline and Market Analysis, 2017”, Report to its Comprehensive Database at The report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action.

Key objective of the “Natural Killer Cells-Competitive Landscape, Pipeline and Market Analysis, 2017” report is to establish the understanding for all the marketed and pipeline drugs that fall under Natural Killer Cells.

This report provides information on the therapeutic development based on Natural Killer Cells mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight’s Report also assesses the Natural Killer Cells therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

Browse Report Details at:

Scope of Report:

  • The report provides competitive pipeline landscape of Natural Killer Cells
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Natural Killer Cells
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Natural Killer Cells pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Natural Killer Cells and also provide company profiling
  • The report also gives the information of dormant pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Request a Sample Copy of Report at:

Natural killer cell Therapy Pipeline scenario

  • Monalizumab
  • NKTT-120
  • Ganitumab
  • Herceptin
  • Rituxan
  • Gazyv HER


Collaborations & Partnering deals

  • Lorvotuzumab
  • Mogamulizumab
  • Glycostem Therapeutics
  • Affimed Therapeutics
  • AGNKT Therapeutics
  • Dynavax
  • Multimmune GmbH
  • Kyowa Hakko Kirin Co., Ltd.
  • Altor BioScience Corporation
  • ImmunoGen Inc.
  • Five Prime Therapeutics
  • Fortress Biotech
  • Fate Therapeutics
  • Nantkwest

Buy the Report at:


Reasons to Buy:

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

• Complete MOA intelligence and complete understanding over therapeutics development for Natural Killer Cells

• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.

• Devise corrective measures for pipeline projects by understanding Natural Killer Cells pipeline depth and focus of Indication therapeutics

• Developing strategic initiatives to support your drug development activities.

• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.

• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

For More Enquiry, visit:

About Us:

Orbis Research ( is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Media Contact
Company Name: Orbis Research
Contact Person: Hector Costello
Phone: +1 (214) 884-6817
Address:4144N Central Expressway, Suite 600
City: Dallas
State: Texas
Country: United States